Fortrea Holdings Inc. (NASDAQ: FTRE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.93 | Insider Own | 3.47% | Shs Outstand | 95.10M | Perf Week | 19.15% |
| Market Cap | 1.93B | Forward P/E | 19.07 | EPS next Y | 1.06 | Insider Trans | -7.16% | Shs Float | 94.21M | Perf Month | 15.23% |
| Enterprise Value | 2.88B | PEG | - | EPS next Q | 0.23 | Inst Own | - | Short Float | 12.67% | Perf Quarter | 32.38% |
| Income | -85.00M | P/S | 0.72 | EPS this Y | 190.34% | Inst Trans | - | Short Ratio | 8.26 | Perf Half Y | 104.02% |
| Sales | 2.68B | P/B | 3.68 | EPS next Y | 26.60% | ROA | -3.14% | Short Interest | 11.94M | Perf YTD | 17.57% |
| Book/sh | 5.51 | P/C | 11.41 | EPS next 5Y | 25.33% | ROE | -15.53% | 52W High | 21.39 -5.19% | Perf Year | 101.59% |
| Cash/sh | 1.78 | P/FCF | 10.86 | EPS past 3/5Y | - | ROIC | 0.62% | 52W Low | 8.31 144.04% | Perf 3Y | -26.55% |
| Dividend Est. | - | EV/EBITDA | 35.51 | Sales past 3/5Y | -1.36% 1.08% | Gross Margin | 17.11% | Volatility | 6.76% 4.85% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1.07 | EPS Y/Y TTM | 74.66% | Oper. Margin | 0.41% | ATR (14) | 1.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.96 | Sales Y/Y TTM | -0.70% | Profit Margin | -3.18% | RSI (14) | 64.62 | Recom | 2.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.96 | EPS Q/Q | 21.05% | SMA20 | 10.94% | Beta | 2.04 | Target Price | 20.00 |
| Payout | 0.00% | Debt/Eq | 1.96 | Sales Q/Q | -4.51% | SMA50 | 10.19% | Rel Volume | 1.55 | Prev Close | 19.97 |
| Employees | 14,000 | LT Debt/Eq | 1.95 | Earnings | Nov 05 | SMA200 | 36.21% | Avg Volume | 1.48M | Price | 20.28 |
| IPO Date | Jun 20, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 27.47% 4.73% | Net Debt/EBITDA | 11.69 | Volume | 2,286,808 | Change | 1.55% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | Deutsche Bank | Hold | $18 → $20 |
| Jul-30-26 | Reiterated | Robert W. Baird | $21 → $23 | |
| Jul-30-26 | Reiterated | Barclays | Equal Weight | $18 → $22 |
| Jul-13-26 | Reiterated | Mizuho | Neutral | $15 → $16 |
| Jun-24-26 | Reiterated | Barclays | Equal Weight | $16 → $18 |
| May-07-26 | Reiterated | Deutsche Bank | Hold | $11 → $14 |
| May-06-26 | Reiterated | Truist Financial | Buy | $16 → $19 |
| May-06-26 | Reiterated | Robert W. Baird | $15 → $20 | |
| May-06-26 | Reiterated | Barclays | Equal Weight | $11 → $16 |
| Apr-14-26 | Reiterated | Barclays | Equal Weight | $15 → $11 |
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,677 | 2,723 | 2,696 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,219 | 2,298 | 2,162 | — | — | — | — | |
| Gross Profit | 458 | 426 | 534 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 413 | 456 | 561 | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | |
| Other Operating Expense | 34 | 0 | 135 | — | — | — | — | |
| Operating Income | 11 | -31 | -162 | — | — | — | — | |
| Interest Expense | 84 | 91 | 124 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -5 | -861 | 11 | — | — | — | — | |
| Net Income Before Taxes | -78 | -983 | -275 | — | — | — | — | |
| Income Taxes | 7 | 3 | -3 | — | — | — | — | |
| Consolidated Net Income | -85 | -986 | -328 | — | — | — | — | |
| Net Income From Continuing Operations | -85 | -986 | -271 | — | — | — | — | |
| Net Income | -85 | -986 | -328 | — | — | — | — | |
| EPS (Recurring) | -0.93 | -10.81 | -3.67 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.93 | -10.81 | -3.67 | — | — | — | — | |
| EPS (Diluted) | -0.93 | -10.81 | -3.67 | — | — | — | — | |
| EBITDA | 81 | -814 | -64 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.71 | 0.58 | 0.62 | — | — | — | — | |
| Gross Margin | 17.11 | 15.64 | 19.81 | — | — | — | — | |
| Operating Margin | 0.41 | -1.14 | -6.01 | — | — | — | — | |
| Net Margin | -3.18 | -36.21 | -12.17 | — | — | — | — | |
| Shares Outstanding | 94 | 91 | 90 | — | — | — | — | |
| Market Capitalization | 1,906 | 1,570 | 1,678 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Morais Mark A. | Chief Operating Officer | Sep 09 '26 | Sale | 16.85 | 3,149 | 53,061 | 81,794 | Sep 10 |
| Russell Carrie Elizabeth | Interim CAO | Sep 09 '26 | Sale | 16.85 | 246 | 4,145 | 2,384 | Sep 10 |
| Morais Mark A. | Chief Operating Officer | Sep 08 '26 | Option Exercise | 0.00 | 7,157 | 0 | 84,943 | Sep 10 |
| Russell Carrie Elizabeth | Interim CAO | Sep 08 '26 | Option Exercise | 0.00 | 850 | 0 | 2,630 | Sep 10 |
| Morais Mark A. | Chief Operating Officer | Aug 19 '26 | Sale | 18.19 | 4,892 | 88,985 | 77,786 | Aug 19 |
| Morais Mark A. | Chief Operating Officer | Aug 18 '26 | Option Exercise | 0.00 | 11,313 | 0 | 82,678 | Aug 19 |
| Thakral Anshul | Chief Executive Officer | Aug 06 '26 | Sale | 18.11 | 111,857 | 2,026,284 | 204,940 | Aug 07 |
| Thakral Anshul | Chief Executive Officer | Aug 05 '26 | Sale | 19.16 | 99,869 | 1,913,112 | 316,797 | Aug 06 |
| Thakral Anshul | Chief Executive Officer | Aug 04 '26 | Option Exercise | 0.00 | 416,666 | 0 | 416,666 | Aug 06 |
| SANDERS MACHELLE | Director | Aug 03 '26 | Sale | 18.01 | 9,700 | 174,697 | 36,399 | Aug 05 |
| Smith David Ross | Director | Jul 20 '26 | Option Exercise | 0.00 | 6,598 | 0 | 36,715 | Jul 27 |
| SANDERS MACHELLE | Director | Jun 10 '26 | Option Exercise | 0.00 | 38,817 | 0 | 46,099 | Jun 12 |
| Smith David Ross | Director | Jun 10 '26 | Option Exercise | 0.00 | 38,817 | 0 | 48,361 | Jun 12 |
| Pesicka Edward A | Director | Jun 10 '26 | Option Exercise | 0.00 | 38,817 | 0 | 52,453 | Jun 12 |
| Morais Mark A. | Chief Operating Officer | Jun 10 '26 | Sale | 16.82 | 4,674 | 78,617 | 71,365 | Jun 12 |